NVP-BEP800, also known as BEP-800, is a novel, fully synthetic, orally bioavailable inhibitor that binds to the NH(2)-terminal ATP-binding pocket of Hsp90. NVP-BEP800 showed activity against a panel of human tumor cell lines and primary human xenografts in vitro at nanomolar concentrations. In A375 melanoma and BT-474 breast cancer cell lines, NVP-BEP800 induced client protein degradation (including ErbB2, B-Raf(V600E), Raf-1, and Akt) and Hsp70 induction.
HSP (HSP90) inhibitor Related Prodcuts:
Tanespimycin; Luminespib; Alvespimycin; Ganetespib; BIIB021; Onalespib; SNX-2112; PF-04929113; KW-2478; XL888; Zelavespib (PU-H71); KRIBB11; VER-50589; Triptolide; NVP-HSP990; Dimethylenastron; Geldanamycin